Synthesis and biological evaluation of new β-D-N
DENV-2
Influenza viruses
Nucleosides
RNA-Polymerase
SARS-CoV-2
β-D-N(4)-Hydroxycytidine
β-D-N(4)-O-Isobutyrylcytidine
Journal
Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
12
12
2022
revised:
28
01
2023
accepted:
04
02
2023
pubmed:
11
2
2023
medline:
3
3
2023
entrez:
10
2
2023
Statut:
ppublish
Résumé
Drug repurposing approach was applied to find a potent antiviral agent against RNA viruses such as SARS-CoV-2, influenza viruses and dengue virus with a concise strategy of small change in parent molecular structure. For this purpose, β-D-N
Identifiants
pubmed: 36764470
pii: S0960-894X(23)00052-5
doi: 10.1016/j.bmcl.2023.129174
pmc: PMC9905048
pii:
doi:
Substances chimiques
molnupiravir
YA84KI1VEW
N(4)-hydroxycytidine
C3D11PV2O4
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
129174Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.